Kindred Biosciences founders raise early VC for pet antibody startup VETmAb
What's the deal? TL Foundation has backed VETmAb BiosciencesDealroom has a profile for this one. Try Dealroom →, the San Diego clinical-stage biotech developing monoclonal antibody therapies for chronic diseases in dogs and cats. The early-stage round pairs TL's capital with funding from other investors; its own amount was not disclosed.
Who's behind it? VETmAb is led by co-founder and chief executive officer Denise Bevers, whose previous company, Kindred BiosciencesDealroom has a profile for this one. Try Dealroom →, won four veterinary FDA approvals before Elanco Animal Health acquired it for about $440 million.
Why now? The financing follows positive proof-of-concept results for VMB-C001a, a long-acting anti-IL-23 antibody for canine chronic inflammatory enteropathy. In the pilot study, 77.8% of treated dogs were treatment successes, versus 30.0% on placebo, and the drug has won eligibility for the FDA's expanded conditional approval pathway.
What's the endgame? VMB-C001a leads a five-program pipeline spanning gastrointestinal, immune-mediated, and metabolic disease. The company recently named Katja Buhrer, a former Kindred executive, as chief operating officer to help scale operations and advance its lead program into pivotal development.
What's TL's angle? A 501(c)(3) nonprofit philanthropic venture fund, TL reinvests 100 percent of its returns, charging no management fees or carried interest, to build lasting capital for San Diego startups. "They're experienced local founders recommitting to the very space and community they know so well," said Kris Lichter, its chief executive officer.
The signal: The round reflects renewed interest in companion-animal biotech. San Diego rival Gallant Pet agreed in November to be acquired by DechraDealroom has a profile for this one. Try Dealroom →, which bought antibody developer Invetx in 2024 — signals that strategic buyers are circling the biologics niche VETmAb's seasoned founders have returned to build in.
Read more: Business Insider
Image credit: TL Foundation, via PR Newswire